Acute cellular rejection and the subsequent development of allograft vasculopathy after cardiac transplantation.

[1]  Jason D. Christie,et al.  Registry of the International Society for Heart and Lung Transplantation: twenty-fifth official adult heart transplant report--2008. , 2008, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[2]  G. Sanz,et al.  Effects of cyclosporine, tacrolimus and sirolimus on vascular changes related to immune response. , 2008, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[3]  W. Kremers,et al.  Conversion to Sirolimus as Primary Immunosuppression Attenuates the Progression of Allograft Vasculopathy After Cardiac Transplantation , 2007, Circulation.

[4]  W. Kremers,et al.  Replacement of Calcineurin-Inhibitors With Sirolimus as Primary Immunosuppression in Stable Cardiac Transplant Recipients , 2007, Transplantation.

[5]  J. Platt,et al.  Accommodation of grafts: implications for health and disease. , 2007, Human immunology.

[6]  Paul Aurora,et al.  Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult heart transplant report--2007. , 2007, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[7]  W. Kremers,et al.  Systemic inflammation and metabolic syndrome in cardiac allograft vasculopathy. , 2007, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[8]  P. Serruys,et al.  Plaque composition in the left main stem mimics the distal but not the proximal tract of the left coronary artery: influence of clinical presentation, length of the left main trunk, lipid profile, and systemic levels of C-reactive protein. , 2007, Journal of the American College of Cardiology.

[9]  D. Holmes,et al.  Association of angiotensin-converting enzyme inhibitors and serum lipids with plaque regression in cardiac allograft vasculopathy. , 2006, Transplantation.

[10]  Marshall I Hertz,et al.  Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult lung and heart-lung transplantation report--2006. , 2006, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[11]  H. Ly,et al.  In-stent restenosis and remote coronary lesion progression are coupled in cardiac transplant vasculopathy but not in native coronary artery disease. , 2006, Journal of the American College of Cardiology.

[12]  R. Virmani,et al.  Accuracy of in vivo coronary plaque morphology assessment: a validation study of in vivo virtual histology compared with in vitro histopathology. , 2006, Journal of the American College of Cardiology.

[13]  A. Knez,et al.  Preventing cardiac allograft vasculopathy: long-term beneficial effects of mycophenolate mofetil. , 2006, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[14]  E. Mahmud,et al.  Imaging vulnerable plaque by ultrasound. , 2006, Journal of the American College of Cardiology.

[15]  J. Kobashigawa,et al.  The revised ISHLT heart biopsy grading scale. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[16]  L. Sharples,et al.  The cumulative effect of acute rejection on development of cardiac allograft vasculopathy. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[17]  P. Macdonald,et al.  Sirolimus in De Novo Heart Transplant Recipients Reduces Acute Rejection and Prevents Coronary Artery Disease at 2 Years: A Randomized Clinical Trial , 2004, Circulation.

[18]  D. Carey,et al.  Rapamycin suppresses experimental aortic aneurysm growth. , 2004, Journal of vascular surgery.

[19]  A. Angelini,et al.  Immune and Nonimmune Predictors of Cardiac Allograft Vasculopathy Onset and Severity: Multivariate Risk Factor Analysis and Role of Immunosuppression , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[20]  G. Mintz,et al.  Volumetric Analysis of In-Stent Intimal Hyperplasia in Diabetic Patients Treated With or Without Abciximab: Results of the Diabetes Abciximab steNT Evaluation (DANTE) Randomized Trial , 2004, Circulation.

[21]  Antonio Colombo,et al.  From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. , 2003, Circulation.

[22]  E. Boerwinkle,et al.  From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. , 2003, Circulation.

[23]  James A. White,et al.  Validation of a three-dimensional intravascular ultrasound imaging technique to assess atherosclerotic burden: potential for improved assessment of cardiac allograft coronary artery disease. , 2003, The Canadian journal of cardiology.

[24]  E. Wellnhofer,et al.  Association between acute rejection and cardiac allograft vasculopathy. , 2003, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[25]  Christopher H Jackson,et al.  Diagnostic accuracy of coronary angiography and risk factors for post–heart-transplant cardiac allograft vasculopathy , 2003, Transplantation.

[26]  K. Endresen,et al.  Plasma C-reactive protein as a marker of cardiac allograft vasculopathy in heart transplant recipients. , 2003, Journal of the American College of Cardiology.

[27]  L. V. von Segesser,et al.  Alloimmunity and nonimmunologic risk factors in cardiac allograft vasculopathy. , 2003, European heart journal.

[28]  D. Nelson,et al.  Non-immunologic vascular failure of the transplanted heart. , 2003, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[29]  E. Tuzcu,et al.  Coronary Plaque Classification With Intravascular Ultrasound Radiofrequency Data Analysis , 2002, Circulation.

[30]  E. Tuzcu,et al.  Myocardial ischemic-fibrotic injury after human heart transplantation is associated with increased progression of vasculopathy, decreased cellular rejection and poor long-term outcome. , 2002, Journal of the American College of Cardiology.

[31]  N. Obuchowski,et al.  Assessing spectral algorithms to predict atherosclerotic plaque composition with normalized and raw intravascular ultrasound data. , 2001, Ultrasound in Medicine and Biology.

[32]  S. Kapadia,et al.  Cellular rejection and rate of progression of transplant vasculopathy: a 3-year serial intravascular ultrasound study. , 2001, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[33]  A. Haverich,et al.  Systemic Inflammatory Response in Cardiac Allograft Vasculopathy: High-Sensitive C-Reactive Protein Is Associated With Progressive Luminal Obstruction , 2000, Circulation.

[34]  L. Rabbani,et al.  Elevated Levels of Plasma C-Reactive Protein Are Associated With Decreased Graft Survival in Cardiac Transplant Recipients , 2000, Circulation.

[35]  O. Hess,et al.  Incidence, progression and functional significance of cardiac allograft vasculopathy after heart transplantation. , 2000, Transplantation.

[36]  E. Tuzcu,et al.  Intravascular ultrasound imaging after cardiac transplantation: advantage of multi-vessel imaging. , 2000, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[37]  J. Pober,et al.  Interferon-γ elicits arteriosclerosis in the absence of leukocytes , 2000, Nature.

[38]  L. Miller,et al.  Heart transplant coronary artery disease detected by coronary angiography: a multiinstitutional study of preoperative donor and recipient risk factors. Cardiac Transplant Research Database. , 1998, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[39]  I. Carrió,et al.  Efficacy of augmented immunosuppressive therapy for early vasculopathy in heart transplantation. , 1998, Journal of the American College of Cardiology.

[40]  M. Turina,et al.  Cardiac allograft rejection late after transplantation is a risk factor for graft coronary artery disease. , 1998, Transplantation.

[41]  M. Yacoub,et al.  Influence of acute rejection episodes, HLA matching, and donor/recipient phenotype on the development of 'early' transplant-associated coronary artery disease. , 1997, Circulation.

[42]  M. Mehra,et al.  The prognostic impact of immunosuppression and cellular rejection on cardiac allograft vasculopathy: time for a reappraisal. , 1997, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[43]  G. Opelz.  Critical evaluation of the association of acute with chronic graft rejection in kidney and heart transplant recipients. The Collaborative Transplant Study. , 1997, Transplantation proceedings.

[44]  E. Arbustini,et al.  Morphological observations in the epicardial coronary arteries and their surroundings late after cardiac transplantation (allograft vascular disease) , 1996, The American journal of cardiology.

[45]  S. Hunt,et al.  Prognostic importance of intimal thickness as measured by intracoronary ultrasound after cardiac transplantation. , 1995, Circulation.

[46]  A. Yeung,et al.  Does acute rejection correlate with the development of transplant coronary artery disease? A multicenter study using intravascular ultrasound. Sandoz/CVIS Investigators. , 1995, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[47]  P. Uberfuhr,et al.  Qualitative and quantitative assessment of cardiac allograft vasculopathy by intravascular ultrasound. , 1995, Transplantation proceedings.

[48]  F. Schoen,et al.  Natural history of focal moderate cardiac allograft rejection. Is treatment warranted? , 1995, Circulation.

[49]  C. White-Williams,et al.  Treatment of recurrent heart rejection with mycophenolate mofetil (RS-61443): initial clinical experience. , 1994, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[50]  M. Masek,et al.  Cardiac graft vascular disease. Nonselective involvement of large and small vessels. , 1993, Transplantation.

[51]  S. Hunt,et al.  Influence of graft rejection on incidence of accelerated graft coronary artery disease: a new approach to analysis. , 1993, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[52]  D. Renlund,et al.  Task force 5: Complications , 1993 .

[53]  J. Atkinson,et al.  Clinical Significance of Mild Rejection of the Cardiac Allograft , 1992, Circulation.

[54]  I. Bassanetti,et al.  Evolution of untreated mild rejection in heart transplant recipients. , 1992, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[55]  M. Billingham.  Histopathology of graft coronary disease. , 1992, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[56]  R. Kormos,et al.  Acute rejection and coronary artery disease in long-term survivors of heart transplantation. , 1989, The Journal of heart transplantation.

[57]  M E Billingham,et al.  Cardiac transplant atherosclerosis. , 1987, Transplantation proceedings.

[58]  T. English,et al.  Lack of association between endomyocardial evidence of rejection in the first six months and the later development of transplant-related coronary artery disease. , 1993, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.